Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410465 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL19658254 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL19658247 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL17776321 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL18751700 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL17776273 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL17776275 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL10086616 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL17776322 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL | |
| SCHEMBL29687696 | 1.00 | PSMB8 (0.32) | PSMB8PSMB5ALOX12MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20240400672-A1 | NOVEL MONOCLONAL ANTIBODIES DIRECTED AGAINST L-THYROXINE AND DIAGNOSTIC USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-05 | — | — | US | disclosed |
| EP-4430074-A1 | NOVEL MONOCLONAL ANTIBODIES DIRECTED AGAINST L-THYROXINE AND DIAGNOSTIC USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2024-09-18 | — | — | EP | disclosed |
| CN-118265723-A | Novel monoclonal antibodies directed against L-thyroxine and diagnostic uses thereof | 豪夫迈·罗氏有限公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024105205-A1 | ANTIBODY-DRUG CONJUGATES (A2DCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |
| US-11826485-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4210729-A2 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4204441-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
| US-9393344-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| WO-2016081670-A2 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | WO | disclosed |
| US-20130244939-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130130979-A1 | PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8304391-B2 | Peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20090227508-A1 | PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-7528104-B2 | Peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070196454-A1 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070027074-A1 | Novel peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244939-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | PSMB8 1476/4885PSMB5 1020/4885ALOX12 4083/4885 |
| US-11826485-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, LIG3, PLOD2 | PSMB8 3132/4885PSMB5 3873/4885ALOX12 2153/4885 |
| US-20070196454-A1 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, PLOD2, PLOD1 | PSMB8 2785/4885PSMB5 3153/4885ALOX12 2752/4885 |
| US-20090227508-A1 | PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | PSMB8 1601/4885PSMB5 1092/4885ALOX12 3872/4885 |
| US-20130130979-A1 | PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | PSMB8 1601/4885PSMB5 1092/4885ALOX12 3872/4885 |
| US-20070027074-A1 | Novel peptides that bind to the erythropoietin receptor | EPOR, PROKR1, EDNRB | PSMB8 1476/4885PSMB5 1020/4885ALOX12 4083/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | PSMB8 908/4885PSMB5 1149/4885ALOX12 2426/4885 |
| US-20240400672-A1 | NOVEL MONOCLONAL ANTIBODIES DIRECTED AGAINST L-THYROXINE AND DIAGNOSTIC USES THEREOF | IGLV6-57, THRB, TSHR | PSMB8 1565/4885PSMB5 99/4885ALOX12 4657/4885 |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | PSMB8 621/4885PSMB5 1651/4885ALOX12 4142/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | PSMB8 621/4885PSMB5 1651/4885ALOX12 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.